Claude Piche, PhD
Board Chair; Co-Creator and CEO, Locemia Solutions
As Co-Founder, President and CEO of Locemia Solutions, Dr. Piché led the company from start up through to completion of phase III clinical studies, ultimately resulting in the sale of its glucagon nasal powder technology to Eli Lilly in October 2015. He has over 25 years of experience in developing and commercializing pharmaceuticals, vaccines, and diagnostics, including more than 15 years where he focused on diabetes therapeutics and hypoglycemia-related technologies. He has worked at large companies such as Merck, as well as start-up biopharmaceutical companies where he had roles in research, regulatory affairs, marketing, and operations.
Board Member, InMed Pharmaceuticals
Andrew Hull is an accomplished national and global executive with more than 30 years experience in various commercial and business development roles with leading pharmaceutical and biotech companies. He most recently served as Head of Global Alliances for Takeda Pharmaceuticals. Andrew has a track record of leading marketing and development projects, growing organizations’ scale, and developing global strategic partnerships.
Michael R. Martin
Chief Operating Officer of Aurinia Pharmaceuticals Inc.
Michael R. Martin is the current Chief Operating Officer of Aurinia Pharmaceuticals Inc., and has over 23 years of experience in the biopharmaceutical industry. Michael co-founded Aurinia taking it from a small privately held company in 2013 to a publicly listed company worth nearly half a billion dollars. Having held various previous senior commercial positions with extensive experience executing complex business transactions as well as raising capital, Michael was also a key member of the business development team that saw Aspreva sold to Galenica for $915M.
Parimal Nathwani, MSc, MBA
Vice President, Life Sciences, MaRS Innovation
Parimal Nathwani has over 15 years of experience in various aspects of the biotechnology industry, including corporate finance, business development, transactions, intellectual property management, technology development and operations. He has been actively involved in forming and managing start-ups, preparing and executing on business plans, raising early-stage capital, and in- and out-licensing activities.
Before joining MaRS Innovation, Parimal was a healthcare analyst with a boutique investment bank, where he conducted equity research on publicly-traded biotechnology companies in Canada and the U.S. He has also led commercialization activities out of BC Women’s and Children’s Hospital as part of his role at the University of British Columbia’s Industry Liaison Office, and was a research scientist at a start-up biotechnology company involved in drug discovery targeting ABC Transporters.
Parimal received his MBA from Simon Fraser University and his M.Sc. from the University of British Columbia. He currently sits on the board of ScarX Therapeutics (Chairman), Zucara Therapeutics, and is an observer on the boards of Encycle Therapeutics and Vasomune Therapeutics.
Michael Midmer, MSc, MBA
Chief Executive Officer, Zucara Therapeutics
Michael has over 15 years of experience in the life science industry, fund management and corporate finance. Michael was formerly the Director of the Genomic Applications Partnership Program (GAPP) at Genome Canada. The GAPP program funded partnerships between industry and academia including companies such as Xagenic, Vasomune, Assurex and Roche.
Before joining Genome Canada, Michael was a Director at Rosetta Capital, an international venture capital firm, where he managed a portfolio of over 30 companies in North America and Europe including company exits such as Enobia, Cytochroma, Ambit and Resonant. Michael was also Business Development Manager at KS Biomedix and was Investor Relations Manager at Cardiome Pharma. In addition, Michael has been a board member for several companies and was the Chair of a not-for-profit board.
Michael has an MSc in molecular biology from the University of Toronto (Canada) and an MBA from Imperial College Business School (UK). He has also completed the Canadian Securities Course.